Surrozen Inc Total Liabilities
Surrozen Inc total liabilities. Based on the latest financial reports, Surrozen Inc (SRZN) has total liabilities worth $334.27 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SRZN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Surrozen Inc (2019–2025)
Total liabilities of Surrozen Inc from 2019 to 2025. This chart illustrates how Surrozen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Surrozen Inc to see how much of total assets are deployed in long-term investments.
Surrozen Inc Competitors by Total Liabilities
The table below lists competitors of Surrozen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Apartment Investment and Management Co
NYSE:AIV
|
USA | $727.94 Million |
|
ThredUp Inc
NASDAQ:TDUP
|
USA | $109.39 Million |
|
Bank Of Princeton
NASDAQ:BPRN
|
USA | $2.01 Billion |
|
CS Disco LLC
NYSE:LAW
|
USA | $38.42 Million |
|
COG Financial Services Ltd
AU:COG
|
Australia | AU$536.47 Million |
|
Jena Acquisition Corporation II
NYSE:JENA
|
USA | $14.61 Million |
|
Eisen- und Hüttenwerke AG
F:EIS
|
Germany | €2.12 Million |
|
Lanzhou Zhuangyuan Pasture Co Ltd
SHE:002910
|
China | CN¥1.24 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Surrozen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SRZN current and non-current assets.
Liquidity & Leverage Metrics
Surrozen Inc Total Liabilities Ratios Explained
Surrozen Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Surrozen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Surrozen Inc (2019–2025)
The table below shows the annual total liabilities of Surrozen Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $286.49 Million | +310.17% |
| 2024-12-31 | $69.85 Million | +757.54% |
| 2023-12-31 | $8.14 Million | -39.37% |
| 2022-12-31 | $13.43 Million | -51.10% |
| 2021-12-31 | $27.47 Million | +86.05% |
| 2020-12-31 | $14.77 Million | +12.73% |
| 2019-12-31 | $13.10 Million | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more